LEXICON PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-12.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2021-03-12
- LEXICON PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2020 was $0.00.
- LEXICON PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- LEXICON PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2018 was $978.00K.
- LEXICON PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2017 was -$1.99M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month as first filed |
|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-12 | |
| 2019-12-31 | $0.00 10-K · filed 2021-03-12 | |
| 2018-12-31 | $978.00K 10-K · filed 2021-03-12 | -$978.00K 10-K · filed 2020-03-12 |
| 2017-12-31 | -$1.99M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |